Healthcare insurance company Molina Healthcare (NYSE:MOH) reported Q1 CY2025 results beating Wall Street’s revenue expectations , with sales up 12.2% year on year to $11.15 billion. Its non-GAAP profit of $6.08 per share was 2.1% above analysts’ consensus estimates.

Is now the time to buy MOH? Find out in our full research report (it’s free).

Molina Healthcare (MOH) Q1 CY2025 Highlights:

Revenue: $11.15 billion vs analyst estimates of $10.86 billion (12.2% year-on-year growth, 2.6% beat) Adjusted EPS: $6.08 vs analyst estimates of $5.96 (2.1% beat) Adjusted EBITDA: $506 million vs analyst estimates of $520.8 million (4.5% margin, 2.8% miss) Adjusted EPS guidance for the full year is $24.50 at the midpoint, roughly in line with what analysts were expecting Operating Margin: 3.9%, in line with the same quarter last year Free Cash Flow Margin: 1.5%, similar to the same quarter last year Customers: 5.75 million, up from 5.54 million in the previous quarter Market Capitalization: $17.46 billion

StockStory’s Take

Molina Healthcare’s first quarter was shaped by continued growth in its core government-sponsored health plans and disciplined management of medical costs. CEO Joe Zubretsky emphasized that the company’s 12% year-over-year revenue growth reflected both organic gains and contributions from recent contract awards, especially within Medicaid and Medicare dual eligible segments. The management team attributed stable margins to effective rate negotiations and cost controls, despite some seasonal pressures and higher utilization in specific areas such as long-term services and behavioral health.

Looking ahead, Molina reaffirmed its adjusted earnings guidance for the year, with management expressing confidence in its embedded earnings power and future contract wins. CFO Mark Keim noted that updated Medicaid rates are expected to offset higher medical cost trends, and the company remains focused on integrating new membership from recent acquisitions and RFP awards. Zubretsky concluded, "Our 2025 earnings and growth profiles are solid, and we remain very confident in our ability to achieve our long-term growth targets."

Key Insights from Management’s Remarks

Molina Healthcare’s Q1 performance was influenced by membership gains and cost management, while non-recurring items affected marketplace margins. Management detailed drivers of the quarter’s results and outlined ongoing business initiatives:

Medicaid rate updates: Molina secured higher-than-expected rate adjustments from state partners, which management said will help address rising costs for services like long-term care and specialty drugs in subsequent quarters. Marketplace margin volatility: The company’s ACA Marketplace segment experienced elevated medical cost ratios due to one-time items, including risk adjustment true-ups and membership reconciliation issues, particularly from the ConnectiCare acquisition. Management expects these impacts to normalize going forward. Contract wins and embedded earnings: Molina defended its Medicaid position in Nevada and expanded its dual eligible Medicare business in Illinois, adding meaningful incremental revenue and supporting management’s long-term premium targets. M&A pipeline and integration: The acquisition pipeline remains active, with the company signaling ongoing interest in regional players. Integration of prior deals, such as ConnectiCare, is expected to contribute to earnings as operational improvements are realized. Stable legislative environment: Management noted that anticipated changes to Medicaid funding at the federal level are likely to be marginal in the near term. They believe any legislative adjustments will be gradual and manageable from a business perspective.

Story Continues

Drivers of Future Performance

Management sees Molina’s growth in the next quarters as hinging on successful rate negotiations, disciplined cost controls, and the integration of new members from contract wins and acquisitions.

Rate adequacy and cost trends: Adjustments to Medicaid rates are expected to match higher medical cost trends, but management is applying early-year conservatism and will reassess as the year progresses. Membership expansion: Recent RFP victories and acquisition-related growth are projected to drive higher revenue, with the company targeting operational improvements to achieve mid-single-digit margins in the Marketplace segment. Policy and regulatory risks: Potential shifts in Medicaid funding or program rules could affect membership and reimbursement, but management currently sees limited risk of disruptive policy changes in the short term.

Top Analyst Questions

Stephen Baxter (Wells Fargo): Asked for clarification on non-recurring items impacting Marketplace margins. Management explained that risk adjustment and member reconciliation issues were one-time events and should not affect future quarters. Andrew Mok (Barclays): Inquired about Medicaid rate and cost trend assumptions. Management detailed how updated rates were offset by conservative cost trend estimates, maintaining margin guidance. Josh Raskin (Nephron Research): Questioned the strategic role of Marketplace in Molina’s portfolio. CEO Joe Zubretsky described it as synergistic with Medicaid and Medicare, enabling member retention across life stages. Ryan Langston (TD Cowen): Probed whether policy uncertainty was affecting M&A appetite. Management stated that the acquisition pipeline remains full, with underperforming single-state operators seeking partnerships. Lance Wilkes (Bernstein): Asked about network contracting and value-based care. Management noted compliance with regulatory standards and continued efforts to expand value-based arrangements, especially in Medicaid.

Catalysts in Upcoming Quarters

Over the coming quarters, the StockStory team will monitor (1) the pace at which Molina integrates new members from recent contract wins and acquisitions, (2) whether Medicaid rate increases keep pace with rising medical cost trends, and (3) the stabilization of Marketplace margins following one-time items. Execution on M&A opportunities and updates on federal or state policy changes will also be important signposts for Molina’s trajectory.

Molina Healthcare currently trades at a forward P/E ratio of 12.6×. At this valuation, is it a buy or sell post earnings? The answer lies in our free research report.

The Best Stocks for High-Quality Investors

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

View Comments